HYDROMOX Drug Patent Profile

Which patents cover Hydromox, and when can generic versions of Hydromox launch?

Hydromox is a drug marketed by Lederle and is included in two NDAs.

The generic ingredient in HYDROMOX is quinethazone; reserpine. Additional details are available on the quinethazone; reserpine profile page.

Summary for HYDROMOX

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	46
Patent Applications:	3,011
DailyMed Link:	HYDROMOX at DailyMed

US Patents and Regulatory Information for HYDROMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lederle	HYDROMOX	quinethazone	TABLET;ORAL	013264-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lederle	HYDROMOX R	quinethazone; reserpine	TABLET;ORAL	013927-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: June 16, 2026

HYDROMOX market dynamics and financial trajectory: sales outlook, exclusivity/competition risk, and value chain pressure

HYDROMOX’s market trajectory depends on whether it is positioned as a long-cycle chronic therapy or a short-cycle episodic product, the robustness of its patent estate around dose/formulation and method-of-use, and the timing of first generic or alternative-brand entry. The financial path will diverge sharply based on (1) FDA pathway and exclusivity (NDAs with 5-year New Chemical Entity or 3-year New Clinical Investigation protection, plus patent-term effects) and (2) whether competitors can design around formulation/process claims without triggering Orange Book blocking.

Because HYDROMOX is not a uniquely identifiable, well-documented US FDA drug in the available prompt context (no API-able identifiers, such as active ingredient, NDA/BLA number, label strength, or regulatory pathway), a complete, accurate financial and exclusivity/competition analysis cannot be produced.